Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 26.25% for Sage Therapeutics (SAGE) based on the company’s closing price on March 27. Analysts revised the company’s target price downward twice, from $201.06 in January to $200.56 in February and then to $200.44 in March.

The current consensus analyst recommendation for the stock is a “buy.”

Most Analysts Have Been Positive on Sage Therapeutics in March

Of the 17 analysts covering Sage Therapeutics, eight are recommending “strong buys,” eight are recommending “buys,” and one is recommending a “sell.” The highest and lowest target price estimates for the company are $249 and $90, respectively.

On March 27, Sage Therapeutics closed at $158.76, 2.99% lower than its previous closing price, 98.75% higher than its 52-week low of $79.88, and 15.92% lower than its 52-week high of $188.82.

Based on its closing price on March 27, Sage Therapeutics has reported returns of 4.13% in the last week, 3.93% in the last month, and 89.97% in the last quarter. The company has reported returns of -8.73% in the last half year, 1.62% in the last year, and 65.74% year-to-date.

Growth trends

On January 7, Sage Therapeutics issued a press release announcing positive top line results from its Phase 3 ROBIN trial evaluating SAGE-217 in postpartum depression indications. Thereafter, the company’s share price jumped 42.68% and closed at $139.13 on January 7.

Sage Therapeutics is currently enrolling patients in its Phase 3 MOUNTAIN study to evaluate SAGE-217 in MDD (major depressive disorder) indications. Top line results from this trial are expected in the fourth quarter of 2019 or the first quarter of 2020.

According to the company’s fourth-quarter earnings conference call, it’s also studying SAGE-217 in its RAINFOREST study for patients suffering from MDD and comorbid insomnia.

On March 19, Sage Therapeutics issued a press release announcing the FDA’s approval of its drug Zulresso in postpartum depression indications.

Latest articles

Today, Canopy Growth announced that it acquired the Saskatchewan-based KeyLeaf Life Sciences along with entities relating to the company and its intellectual property. Here's what you need to know about the completed deal.

Yesterday, Tyson Foods (TSN) and fellow meat producers Pilgrim’s Pride (PPC) and Sanderson Farms (SAFM) took a hit to their stocks after news came out about an investigation over price-fixing allegations.

On June 24, RH (RH) was trading at $115.01, implying a rise of 21.2% since its announcement of its first-quarter earnings results on June 12. Despite the surge in its stock price, the company is still trading at a discount of 29.1% to its 52-week high.

26 Jun

Roku Stock Fell Close to 7.0% Yesterday

WRITTEN BY Aditya Raghunath

Roku stock fell 6.8% yesterday to close trading at $93.25 per share. Roku stock has lost over 9.0% in market value in the last two trading days. Prior to this pullback, Roku stock was up a whopping 235.0% year-to-date.

26 Jun

Beyond Meat Stock Up Today on New Product Launch

WRITTEN BY Rajiv Nanjapla

Today, Beyond Meat (BYND) announced that its new product, Beyond Beef, will hit markets across the US later this week.

FedEx (FDX) ended fiscal 2019 on a dismal note and reported a significant YoY decline in fourth-quarter earnings. The delivery giant posted adjusted EPS of $5.01, which was 15.2% lower than the year-ago quarter’s earnings of $5.91. The company cited sluggish revenue growth and increased expenses as the main reason behind the dismal bottom-line performance.